- Home
- ATYR vs ALLT Comparison
ATYR vs ALLT Comparison
Compare ATYR & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- ALLT
- Stock Information
- Founded
- ATYR 2005
- ALLT 1996
- Country
- ATYR United States
- ALLT Israel
- Employees
- ATYR N/A
- ALLT N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- ALLT Telecommunications Equipment
- Sector
- ATYR Health Care
- ALLT Telecommunications
- Exchange
- ATYR Nasdaq
- ALLT Nasdaq
- Market Cap
- ATYR 306.2M
- ALLT 342.5M
- IPO Year
- ATYR 2015
- ALLT 2006
- Fundamental
- Price
- ATYR $5.09
- ALLT $8.35
- Analyst Decision
- ATYR Strong Buy
- ALLT Buy
- Analyst Count
- ATYR 6
- ALLT 1
- Target Price
- ATYR $20.20
- ALLT $13.00
- AVG Volume (30 Days)
- ATYR 3.4M
- ALLT 736.1K
- Earning Date
- ATYR 08-12-2025
- ALLT 08-26-2025
- Dividend Yield
- ATYR N/A
- ALLT N/A
- EPS Growth
- ATYR N/A
- ALLT N/A
- EPS
- ATYR N/A
- ALLT N/A
- Revenue
- ATYR N/A
- ALLT $93,455,000.00
- Revenue This Year
- ATYR $960.85
- ALLT $9.08
- Revenue Next Year
- ATYR $1,283.47
- ALLT $6.09
- P/E Ratio
- ATYR N/A
- ALLT N/A
- Revenue Growth
- ATYR N/A
- ALLT N/A
- 52 Week Low
- ATYR $1.48
- ALLT $2.36
- 52 Week High
- ATYR $5.98
- ALLT $9.92
- Technical
- Relative Strength Index (RSI)
- ATYR 55.16
- ALLT 45.80
- Support Level
- ATYR $4.78
- ALLT $7.86
- Resistance Level
- ATYR $5.50
- ALLT $9.92
- Average True Range (ATR)
- ATYR 0.37
- ALLT 0.43
- MACD
- ATYR -0.09
- ALLT -0.12
- Stochastic Oscillator
- ATYR 25.68
- ALLT 14.73
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.